ANZCTR search results

Comparison of new biodegradable foam against commercially available non-biodegradable foam under topical negative pressure dressings for safety and efficacy in transmitting the vacuum to the wound bed.

This study will be a national clinical trial that will evaluate the safety and efficacy of a chemotherapy treatment, administered to adolescents and young adults with a newly diagnosed bone marrow cancer, called acute lymphoblastic leukaemia (ALL). Who is it for? You may be able to join this study if you are aged between 15 to 40 years and have been recently diagnosed with acute lymphoblastic leukaemia (ALL), for which you have not yet undergone any treatment. Trial details: ALL is the most common form of childhood cancer, but in over 80% of children it can be cured with chemotherapy. Adults with ALL do much worse and this trial will examine whether exactly the same treatment given to children can also be given to adults, and if so, are the results as good. In order to determine this, all patients in this trial will be administered the same chemotherapy treatment given to children. Patients' response to this chemotherapy will determine subsequent treatment. Participants in this trial will be regularly assessed throughout this trial to determine remission rates, survival, toxicity and quality of life.

The primary aims of the study include 1)to determine whether 8 weeks of exercise-based videogame exercise performed at home independently by a chronic stroke survivor is feasible; and 2) to determine whether exercise-based videogames used at home independently by a chronic stroke survivor improve upper and lower limb motor coordination. A single-subject randomised controlled trial design will be used. The participant is an independently-living 51 year old long-term male stroke survivor with ongoing lower limb and upper limb motor coordination problems on his affected side. The participant will practise upper limb and lower limb exercise-based videogames independently at home over an 8-week period (2 x 2 weeks of upper limb exercise-based videogames, and 2 x 2 weeks of lower limb exercise-based videogames). The order of the upper limb and lower limb exercise periods will be randomised. The participant will practise the games as much as possible during his normal daily routine. The primary outcomes include choice stepping time (lower limb) and arm reach reaction time (upper limb). Secondary outcomes include the High-level Mobility Assessment Tool, tandem walk, step test, 6-minute walk, upper limb items of the Motor Assessment Scale, Box-and-Block Test, Action Research Arm Test, System Usability Scale, and subjective gait video assessment. This study will provide valuable information on the feasibility and efficacy of using exercise-based videogame exercises in the home after stroke

To determine whether a commonly used medication for blood pressure (felodipine) could be a cause of interactions with other medication that can lead to adverse effects.

Tai Ji or Tai Chi (TC) is an ancient Chinese mind body exercise that is practised worldwide by millions of people daily with the belief that it has the potent healing effects upon the practitioner and a fundamental path for longevity. Whilst the mechanisms behind TC are not fully understood it is a general consensus among the general population that TC calms the mind and benefits health. There has been growing interest in the scientific community to evaluate the efficacy of TC in various physiological and psychological conditions; in particular the therapeutic effects of TC in psychological conditions. This study will hope to evaluate whether TC can improve stress level as measured by the State/trait anxiety scale and several objective physiological measures such as blood pressure, heart rate variability and galvanic skin response in a clinical trial with thirty participants. The participants will be randomly allocated by computer to three equal sized groups (n=10 per group), the TC intervention group, Gym group and Waiting list. The TC intervention group will complete five hours of TC exercise per week (minimum 2 contact hours with the instructor) over a period of 6sixweeks and followed by six weeks of self practise. The gym group will receive 12 weeks of free gym membership at the UTS Fitness centre, whilst the waiting list forms the non-active control group. The waiting list group will however be given six weeks of TC class after the experimental period as thanks for participation in the trial. The primary aim of this study is to evaluate if six weeks of TC practise can significantly reduce levels of stress in healthy but stressed individuals compared to a waiting list and if TC practise is equivalent to standard exercise in controlling stress levels. The trial will also evaluate if the effects of TC practise on stress can also be sustained when individuals are asked to practise without guidance and the comparative results of this compared to both waiting list and standard exercise groups. The primary measure will be the State/trait anxiety inventory and secondary measures will be blood pressure, SF36 (Short Form 36 questions to assess general health status), heart rate variability and a Visual Analogue Scale (VAS) on their perceived level of stress.

The aim of this study is to compare a synbiotic supplement containing pre- and probiotics, bovine lactoferrin and bovine immunoglobulines with acacia gum on gut bacteria and indices of immunity. The study will provide consumers with evidence based advice on the use of a synbiotic supplement.

The purpose of this study is to find out if the drug “Vessel Dilator” (VSDL) is absorbed from an injection under the skin and whether it improves heart function in people diagnosed with stable chronic heart failure and a moderate degree of kidney function loss. additionally, the study will find out if Vessel Dilator has effects on kidney function.

The purpose of this retrospective study was to assess ET patients who were treated with different anti-platelet agents and to elucidate the risk factors, gender prevalence and molecular genetics within different treatment modalities for ET. This study aims to evaluate drug tolerance and response to the treatment with hydroxyurea, anagrelide, IFN a and aspirin (either alone or in combination with the three aforementioned cytoreductive therapies). Furthermore, exploratory analysis of full blood counts (FBC) and JAK2 mutation results of all patients were conducted in order to establish any correlation between these haematological indices, treatment and disease outcomes, with the purpose of aiding clinicians to recognise the best treatment approach and improve the disease outcome by using the most appropriate management.

Cystic fibrosis (CF) is a progressive, multi-system genetic disorder that increases in complexity and severity with age. A substantial increase in survival has occurred over the past 50 years and where previously affected individuals died predominantly in childhood, this is now a rare event. CF population projections predict that the majority of children now living with CF will survive into their fifth decade. The challenge facing adult healthcare providers is how to consolidate the gains made during paediatric care and to assist adult CF patients to manage a condition made increasingly complex by the onset of CF-related diabetes, progressive lung and liver disease, and osteoporosis in the context of trying to lead an independent life. Equipping individuals affected by chronic disease with skills to self-manage has been shown to improve both health-related outcomes and quality of life, but there has been little work in CF in this area. The aim of this pilot study is to assess the feasibility of a mentor-based behavioural modification intervention to enhance self-efficacy to self-manage, with some individuals utilizing an information and communication technology (IT) tool - a modified mobile phone - that enabled self-recording of symptoms with immediate visual feedback on reported symptoms.

This study will evaluate the safety and efficacy of intraperitoneal administration (injection into the abdomen) of a drug called bevacizumab in patients with ascites due to advanced chemotherapy resistant gynaecological cancers. Who is it for? You may be eligible join this study if you are a female aged 18 years or more and have symptomatic ascites due to chemotherapy resistant gynaecological cancer. You must have required at least one therapeutic ascitic draining in the 4 weeks prior to study registration. Trial details All participants in this trial will undergo therapeutic draining of malignant ascites as per local institutional protocol. This will then be followed by intraperitoneal administration (injection into the abdomen) of the drug bevacizumab at a dose of 5mg/kg. This treatment may be repeated while on study. Participants will be assessed to determine whether this treatment can reduce the formation of ascites and delay the time to re-accumulation of ascitic fluid. The duration of participation will up to three months after the initial on-study ascitic drainage and bevacizumab infusion.